Heart Disease Trial, Recruiting NCT06995183 Sponsor: E.S.stroes Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06995183
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Elevated Lp(a) group:

  • Men or women aged 50 or older
  • People with an Lp(a) blood level of 150 nmol/L or higher
  • People who were identified through a family screening programme for high Lp(a) levels at the Amsterdam UMC Vascular Medicine outpatient clinic
  • People who are willing and able to give formal consent to take part
  • People who are able to follow the study requirements throughout the trial

Low Lp(a) group:

  • Men or women aged 50 or older
  • People with an Lp(a) blood level below 50 nmol/L
  • People who were identified through a family screening programme for Lp(a) levels at the Amsterdam UMC Vascular Medicine outpatient clinic
  • People who are willing and able to give formal consent to take part
  • People who are able to follow the study requirements throughout the trial

Who may not be able to join:

  • People with significantly reduced kidney function (an eGFR below 30 ml/min)
  • People with a history of heart or blood vessel disease caused by hardening of the arteries — including heart attack, chest pain conditions, stroke, mini-stroke, blocked arteries requiring surgery, or aortic aneurysm
  • People with a history of atrial fibrillation (an irregular heart rhythm condition)
  • People who have used or are currently using statin medications (a common type of cholesterol-lowering medicine)
  • People with any other medical condition or treatment that the trial doctor believes could affect the study results (confirm with trial site)
  • People who are unwilling or unable to give formal consent to take part
  • People who are unable to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +31205669111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
E.S.stroes
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Number of Participants with Coronary Atherosclerotic Plaque Detected on CCTA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov